The past ten years have seen a revolution in therapeutic options for oncology patients. Immune checkpoint inhibitors, chimeric antigen receptor T-cell therapy, and a range of other immuno-oncology techniques designed to rally the adaptive immune system to the patient’s defense have shown extremely promising results across a wide range of indications, often with much more tolerable side-effect profiles than traditional chemotherapy or targeted therapies.
These therapies, however, present special challenges to both treating physicians and those attempting to evaluate the results of clinical trials. In particular, pseudoprogression due to both delayed response to therapy and apparent tumor growth resulting from edema secondary to therapy can confound evaluation of patients undergoing immunotherapy using standard response criteria. This talk will review the biological basis of these confounding factors, discuss the current state of the art in response evaluation in immunotherapy, and explore future avenues for more effective and efficient determination of response to immunotherapy in oncology clinical trials.
Ed Ashton, Ph.D., Vice President, Oncology Imaging, BioTel Research (Cardiocore & VirtualScopics)
Edward Ashton serves as the Vice President of Oncology Imaging for BioTel Research (Cardiocore & VirtualScopics). In this role, he has provided technical leadership on more than 100 clinical trials in oncology and neurology over the past fifteen years. Dr. Ashton is a frequent speaker at international imaging conferences, and has authored many peer-reviewed publications describing his research. Prior to joining BioTel Research, Dr. Ashton was a lead signal processing engineer at The MITRE Corporation in McLean, VA. Earlier in his career, he spent three years as a research engineer with the Naval Research Laboratory, where he received the Alan Berman Research Publication Award and was nominated for the Edison Award for Applied Science. Dr. Ashton has produced numerous articles on target detection and image analysis with military applications. He received both his Ph.D. and M.S. degrees in electrical engineering from the University of Rochester, and his B.S. degree in electrical engineering from Loyola College.
Who Should Attend?
This webinar will benefit medical and non-medical professionals in the biopharmaceutical industry, especially those supporting imaging drug development with roles in:
- Clinical Research
- Clinical Development
- Medical Affairs
- Clinical Operations
- Project Management
- Regulatory Affairs
What You Will Learn
- Review the biological basis of confounding factors in assessing immuno-oncology drugs
- Discuss the current state of the art in response evaluation in immunotherapy
- Explore future avenues for more effective and efficient determination of response to immunotherapy in oncology clinical trials
As leaders in clinical trials services, experts from Cardiocore and VirtualScopics are the Research division of BioTelemetry, Inc., one of the world’s largest connected health companies. As BioTel Research, they offer global operational support for cardiovascular monitoring in all therapeutic areas, and advanced imaging services in oncology, cardiovascular, metabolic, musculoskeletal, neurologic and medical device studies. BioTel Research’s team is comprised of key opinion leaders, radiologists and board-certified cardiologists, sub-specialty scientists, and highly trained technicians — who acquire, evaluate, and report high-quality data through an efficient database infrastructure. For more information please visit www.gobio.com/clinical-research.